Nextcure Inc (NXTC) Stock Price, Quote & News

Company Profile

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease;...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 399 4900

Website: www.nextcure.com

Address:

9000 Virginia Manor Road, Suite 200, Beltsville, United States

CumulativeChaser Aug. 4 at 10:15 AM

$PAPL $XAIR $PASG $NXTC ...

0 · Reply

xgismox Aug. 3 at 9:16 AM

$NXTC https://www.fiercebiotech.com/research/nextcure-antibody-strengthens-bones-mice-rare-brittle-bone-disease?utm_source=chatgpt.com

0 · Reply

xgismox Aug. 2 at 7:15 PM

$NXTC https://www.linkedin.com/pulse/stock-price-plunged-97-can-biotech-co-founded-chen-lieping-vasge

0 · Reply

aNobletrade Jul. 31 at 6:34 PM

https://stocktwits.com/news-articles/markets/equity/nextcure-stock-soars-on-preclinical-data-for-brittle-bone-disease/choGYcvR5v4 $NXTC The fact this ticker is in the news is incredible!! Lord, please make OI a disease of the past 🙏 you know the plans you have for us Lord. Whatever Your Will, let it be done in our lives. Amen Keep up the good work NextCure. My family thanks you for your direction and passion to help remedy this disease

0 · Reply

Homer_Simpson82 Jul. 29 at 3:45 AM

$NXTC yes long play in your head😂

0 · Reply

Quaternity Jul. 28 at 10:38 PM

$NXTC back to posting over and over after missing the easiest long play of last week?

0 · Reply

Homer_Simpson82 Jul. 28 at 10:22 AM

$NXTC see you under 1 soon

0 · Reply

Homer_Simpson82 Jul. 28 at 10:21 AM

$NXTC first short volume. Easy down

0 · Reply

Homer_Simpson82 Jul. 28 at 9:02 AM

$NXTC sooo easy😂😂

0 · Reply

Homer_Simpson82 Jul. 28 at 8:32 AM

$NXTC nice new lows so easy

1 · Reply

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Jun 16, 2025, 10:03 AM EDT - 7 weeks ago

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug

Jun 16, 2025, 7:05 AM EDT - 7 weeks ago

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

May 29, 2025, 4:05 PM EDT - 2 months ago

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

May 1, 2025, 4:05 PM EDT - 3 months ago

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 4, 2025, 7:00 AM EDT - 4 months ago

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

Mar 6, 2025, 4:05 PM EST - 5 months ago

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

Jan 10, 2025, 8:05 AM EST - 7 months ago

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

Dec 10, 2024, 8:05 AM EST - 8 months ago

NextCure Announces Acceptance of IND Application for LNCB74

Nov 26, 2024, 7:00 AM EST - 9 months ago

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

Nov 19, 2024, 8:05 AM EST - 9 months ago

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Nov 7, 2024, 4:05 PM EST - 9 months ago

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 4:05 PM EST - 9 months ago

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 10 months ago

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

Sep 16, 2024, 8:05 AM EDT - 11 months ago

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

Jun 20, 2024, 4:10 PM EDT - 1 year ago

NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

May 30, 2024, 4:05 PM EDT - 1 year ago

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

May 2, 2024, 4:05 PM EDT - 1 year ago

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

Apr 24, 2024, 4:05 PM EDT - 1 year ago

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

Apr 8, 2024, 7:00 AM EDT - 1 year ago

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Apr 4, 2024, 7:05 AM EDT - 1 year ago

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

Apr 2, 2024, 7:00 AM EDT - 1 year ago

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 21, 2024, 8:55 AM EDT - 1 year ago

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Mar 5, 2024, 8:05 AM EST - 1 year ago

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

Jan 18, 2024, 4:05 PM EST - 1 year ago

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Dec 21, 2023, 7:05 AM EST - 1 year ago

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Dec 14, 2023, 6:45 AM EST - 1 year ago

NextCure Provides Year-End Clinical Pipeline Updates

Nov 20, 2023, 7:00 AM EST - 1 year ago

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 15, 2023, 4:05 PM EST - 1 year ago

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

Nov 2, 2023, 4:05 PM EDT - 1 year ago

NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results

Oct 17, 2023, 8:05 AM EDT - 1 year ago

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

Sep 26, 2023, 4:05 PM EDT - 2 years ago

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's Disease

$A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC$

Sep 12, 2023, 8:05 AM EDT - 2 years ago

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

Sep 7, 2023, 4:05 PM EDT - 2 years ago

NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen

Sep 5, 2023, 4:05 PM EDT - 2 years ago

Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease

Aug 31, 2023, 7:00 AM EDT - 2 years ago

NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results

Jun 21, 2023, 4:05 PM EDT - 2 years ago

NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

May 9, 2023, 7:00 AM EDT - 2 years ago

NextCure to Present at the JMP Securities Life Sciences Conference

May 4, 2023, 4:05 PM EDT - 2 years ago

NextCure Provides Business Update and Reports First Quarter 2023 Financial Results

Apr 11, 2023, 7:00 AM EDT - 2 years ago

NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference

Mar 2, 2023, 4:05 PM EST - 2 years ago

NextCure Provides Business Update and Reports Full Year 2022 Financial Results

Feb 7, 2023, 7:00 AM EST - 2 years ago

NextCure to Present at SVB Securities Global Biopharma Conference

Nov 22, 2022, 8:00 AM EST - 2 years ago

NextCure to Present at Upcoming Investor Conferences

Nov 15, 2022, 4:30 PM EST - 2 years ago

NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates

Nov 7, 2022, 8:05 AM EST - 2 years ago

NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

Nov 3, 2022, 4:15 PM EDT - 2 years ago

NextCure Provides Update and Reports Third Quarter 2022 Financial Results

Nov 3, 2022, 9:15 AM EDT - 2 years ago

NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting

Oct 27, 2022, 4:05 PM EDT - 3 years ago

NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

Oct 5, 2022, 8:15 AM EDT - 3 years ago

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

CumulativeChaser Aug. 4 at 10:15 AM

$PAPL $XAIR $PASG $NXTC ...

0 · Reply

xgismox Aug. 3 at 9:16 AM

$NXTC https://www.fiercebiotech.com/research/nextcure-antibody-strengthens-bones-mice-rare-brittle-bone-disease?utm_source=chatgpt.com

0 · Reply

xgismox Aug. 2 at 7:15 PM

$NXTC https://www.linkedin.com/pulse/stock-price-plunged-97-can-biotech-co-founded-chen-lieping-vasge

0 · Reply

aNobletrade Jul. 31 at 6:34 PM

0 · Reply

Homer_Simpson82 Jul. 29 at 3:45 AM

$NXTC yes long play in your head😂

0 · Reply

Quaternity Jul. 28 at 10:38 PM

$NXTC back to posting over and over after missing the easiest long play of last week?

0 · Reply

Homer_Simpson82 Jul. 28 at 10:22 AM

$NXTC see you under 1 soon

0 · Reply

Homer_Simpson82 Jul. 28 at 10:21 AM

$NXTC first short volume. Easy down

0 · Reply

Homer_Simpson82 Jul. 28 at 9:02 AM

$NXTC sooo easy😂😂

0 · Reply

Homer_Simpson82 Jul. 28 at 8:32 AM

$NXTC nice new lows so easy

1 · Reply

Thess5 Jul. 28 at 8:23 AM

$XXII HUGE! Runner! $PROK, $IXHL, $GIBO, $NXTC 💡

1 · Reply

Homer_Simpson82 Jul. 28 at 8:04 AM

$NXTC new lows coming after RS

0 · Reply

ospreyeye Jul. 26 at 11:46 PM

$COUR >> Weekly Chart >> The 100 SMA @ 11.29 = key 🔑 level to hold / downside risk on a drop below If support holds the 200 SMA @ 14.09 = next key 🔑 level to break $SPY $TREE $NXTC $TLYS

0 · Reply

FATSTAX Jul. 26 at 2:42 PM

$SPY $QQQ $NXTC Daily 50 ema = green line 100 ema = yellow line 200 ema = aqua line Pros = white candles Yesterday's pro powered 50 ema breakout makes the build over the $5.90 6/27 high a 100 ema breakout & 200 ema retest threat.

0 · Reply

Homer_Simpson82 Jul. 26 at 9:15 AM

$NXTC yes easy expert

0 · Reply

Homer_Simpson82 Jul. 26 at 9:13 AM

$NXTC perfect scam first RS now new lows. So easy System

0 · Reply

Homer_Simpson82 Jul. 26 at 5:50 AM

$NXTC maybe new lows coming under 1😉

0 · Reply

Homer_Simpson82 Jul. 26 at 4:52 AM

$NXTC where expert 😂

1 · Reply

Homer_Simpson82 Jul. 25 at 7:37 PM

$OCTO $NXTC $GNTX $TOPP $GNLN newbieeee 😂😂

1 · Reply

StockScanners Jul. 25 at 6:04 PM

$NXTC needs to hold above 5.80

1 · Reply

ChicagoBull0780 Jul. 25 at 4:23 PM

$NXTC broke out, took profit 5.6-6.35 🦍🦍 What a day!!

1 · Reply

Boogieboogieboogie Jul. 25 at 4:07 PM

$NXTC recently reverse split and now NEWS! 👀

0 · Reply

Market Cap	13.09M
Revenue (ttm)	0.00
Net Income (ttm)	-55.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	23,043
Avg Vol	143,944
Day's Range	N/A - N/A
Shares Out	2.68M
Stochastic %K	17%
Beta	1.26
Analysts	Strong Sell
Price Target	$25.51